Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction
NL-OMON50612Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing Omecamtiv mecarbil with Placebo (2 arms). Started Jun 2017; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON50612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50612.